Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

These expert-recommended moisturizers can help your skin stay hydrated and healthy. Shop the best body lotions for dry skin ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a ?26.5 million oversubscribed Series A financing from a broad syndicate ...

SAN DIEGO - Dermata Therapeutics , Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW), a biotech firm specializing in skin disease treatments, ...

That’s the message from Cathy O’Brien, CEO of Naturopathica, the botanical skincare brand with five “healing centers” across ...

The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and ...